L. William McIntosh
Chief Executive Officer at Q-RNA, Inc.
Profile
L.
William McIntosh is the founder of Treventis Corp.
He is currently the Chief Executive Officer at Q-RNA, Inc. His former positions include President & Chief Executive Officer at Nexell Therapeutics, Inc., Director at VIRxSYS Corp., Oligomerix, Inc., Signature Capital LLC, Medco Containment Services, Inc., Merck & Co., Inc., Zynaxis, Inc., GSK Plc, and VIMRx Pharmaceuticals, Inc. He was also the Chief Operating Officer at Woodbrook Group Holdings, Inc. and President & Chief Operating Officer at FASgen, Inc. McIntosh received his undergraduate degree and MBA from Lehigh University.
L. William McIntosh active positions
| Companies | Position | Start |
|---|---|---|
Q-RNA, Inc.
 Q-RNA, Inc. Pharmaceuticals: MajorHealth Technology Q-RNA, Inc. develops drugs for the treatment of Alzheimer's disease. The company was founded on August 30, 2002 and is headquartered in New York, NY. | Chief Executive Officer | - |
Treventis Corp.
 Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | Founder | - |
Former positions of L. William McIntosh
| Companies | Position | End |
|---|---|---|
VIRxSYS Corp.
 VIRxSYS Corp. BiotechnologyHealth Technology VIRxSYS Corp. is a holding company, which uses its proprietary platform technologies to develop therapies for serious human diseases. Its platform technologies include lentiviral vectors as a delivery vehicle for genes against certain diseases and for vaccine therapies. Its therapies are in various stages of development from pre-clinical through Phase II clinical trials. The company was founded by Boro Dropulic, William J. Turner, and Wiliam N. Sick Jr in 1998 and is headquartered in Gaithersburg, MD. | President | 2010-04-04 |
| WOODBROOK GROUP HOLDINGS INC. | Chief Operating Officer | 2006-11-30 |
Signature Capital LLC
 Signature Capital LLC Investment ManagersFinance Founded in 1997, Signature Capital LLC is a venture capital firm located in Naples, Florida with an additional office in Portland, Maine | Corporate Officer/Principal | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| VIMRx Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
Training of L. William McIntosh
| Lehigh University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| GSK PLC | Health Technology |
| WOODBROOK GROUP HOLDINGS INC. | Finance |
| Private companies | 11 |
|---|---|
| Medco Containment Services, Inc. | Producer Manufacturing |
Nexell Therapeutics, Inc.
 Nexell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nexell Therapeutics, Inc. develops, manufactures and markets pharmaceutical therapies. Its cell therapy is used for the treatment of genetic blood disorders, autoimmune diseases, cancer, and regenerative medicine applications. The company is headquartered in Irvine, CA. | Health Technology |
Zynaxis, Inc.
 Zynaxis, Inc. Miscellaneous Commercial ServicesCommercial Services Zynaxis, Inc. develops drug delivery systems. The company is based in Malvern, PA. Zynaxis was acquired by Vaxcel, Inc. on December 06, 1996. | Commercial Services |
Q-RNA, Inc.
Q-RNA, Inc. Pharmaceuticals: MajorHealth Technology Q-RNA, Inc. develops drugs for the treatment of Alzheimer's disease. The company was founded on August 30, 2002 and is headquartered in New York, NY. | Health Technology |
VIRxSYS Corp.
VIRxSYS Corp. BiotechnologyHealth Technology VIRxSYS Corp. is a holding company, which uses its proprietary platform technologies to develop therapies for serious human diseases. Its platform technologies include lentiviral vectors as a delivery vehicle for genes against certain diseases and for vaccine therapies. Its therapies are in various stages of development from pre-clinical through Phase II clinical trials. The company was founded by Boro Dropulic, William J. Turner, and Wiliam N. Sick Jr in 1998 and is headquartered in Gaithersburg, MD. | Health Technology |
Oligomerix, Inc.
 Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | Retail Trade |
| VIMRx Pharmaceuticals, Inc. | Health Technology |
Signature Capital LLC
Signature Capital LLC Investment ManagersFinance Founded in 1997, Signature Capital LLC is a venture capital firm located in Naples, Florida with an additional office in Portland, Maine | Finance |
| Boehringer Mannheim Pharmaceuticals Corp. | |
FASgen, Inc.
 FASgen, Inc. Pharmaceuticals: MajorHealth Technology FASgen, Inc. develops novel molecule therapeutics. It provides therapeutic applications for cancer, infectious diseases, and metabolic disorders including obesity and diabetes. The company was founded by James D. Dick, Frank P. Kuhajda, Albert H. Owens, and Craig A. Townsend in 2000 and is headquartered in Baltimore, MD. | Health Technology |
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | Health Technology |
- Stock Market
- Insiders
- L. William McIntosh